Innate Pharma (IPHA) Change in Cash (2019 - 2025)
Innate Pharma's (IPHA) quarterly Change in Cash came in at -$44.6 million in Q4 2025, down 891.34% YoY from $5.6 million in Q4 2024, and down 891.34% on a QoQ basis from -$4.5 million in Q4 2024.
Innate Pharma (IPHA) Change in Cash (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Change in Cash data on file, last reported at -$44.6 million in Q4 2025.
- Quarterly Change in Cash fell 891.34% year-over-year to -$44.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$64.4 million (down 90.74% YoY) and the FY2025 annual result came in at -$44.6 million, down 891.34% from the prior year.
- Change in Cash eased to -$44.6 million in Q4 2025, from -$4.5 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of -$662285.9 in Q2 2024 to a low of -$44.6 million in Q4 2025.
- A 5-year average of -$19.6 million and a median of -$14.7 million in 2023 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2022 — Change in Cash surged 97.82% — and 2023, when it slumped 1520.02%.
- Tracing IPHA's Change in Cash over 5 years: stood at -$37.8 million in 2021, then surged by 47.27% to -$19.9 million in 2022, then climbed by 26.47% to -$14.7 million in 2023, then soared by 69.31% to -$4.5 million in 2024, then sank by 891.34% to -$44.6 million in 2025.
- The last three Change in Cash figures came in at -$44.6 million (Q4 2025), -$4.5 million (Q4 2024), and -$662285.9 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | -44.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -44.59 Mn |
| Dec 31, 2024 | -4.50 Mn |
| Jun 30, 2024 | -662,285.86 |
| Dec 31, 2023 | -14.65 Mn |
| Jun 30, 2023 | -13.95 Mn |
| Dec 31, 2022 | -19.93 Mn |
| Jun 30, 2022 | -861,114.75 |
| Dec 31, 2021 | -37.79 Mn |
| Jun 30, 2021 | -39.51 Mn |
| Dec 31, 2020 | -78.81 Mn |
| Jun 30, 2020 | -78.58 Mn |
| Jun 30, 2019 | -3.30 Mn |